Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.
GRAS
R status
adrenocortical carcinoma
mENSAT
mitotane monotherapy
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Sep 2022
01 Sep 2022
Historique:
received:
02
03
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis for both locally advanced and metastatic disease. Standard treatment with combination etoposide-doxorubicin-cisplatin-mitotane (EDP-M) is highly toxic and some patients benefit from mitotane monotherapy. However, identification of these patients remains challenging. We present a summary of the Israeli national referral center's 20 years of experience in treating advanced ACC, with the aim of identifying prognostic factors and assisting in treatment decision making. We conducted a retrospective multivariate analysis of patients treated for metastatic or locally advanced ACC at Hadassah Medical Center between 2000 and 2020 to determine clinical, pathological, and treatment factors correlated with overall survival (OS). In our cohort of 37 patients, a combination of modified European Network for the study of Adrenal Tumors (mENSAT) staging with either grade and R status, or age and symptoms was validated to stratify prognosis ( Patients with advanced ACC achieving R0 status have a better prognosis and might benefit from mitotane monotherapy.
Identifiants
pubmed: 35949453
doi: 10.1210/jendso/bvac112
pii: bvac112
pmc: PMC9354968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvac112Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Histopathology. 2009 Nov;55(5):535-43
pubmed: 19912359
J Vasc Interv Radiol. 2010 Oct;21(10):1527-32
pubmed: 20801688
Cancer. 2008 Dec 1;113(11):3130-6
pubmed: 18973179
J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84
pubmed: 12466322
Cancer J. 2013 Jul-Aug;19(4):288-94
pubmed: 23867507
Endocr Rev. 2014 Apr;35(2):282-326
pubmed: 24423978
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Ann Oncol. 2015 Oct;26(10):2119-25
pubmed: 26392430
Eur J Cancer. 2010 Mar;46(4):713-9
pubmed: 20044246
Ann Surg Oncol. 2016 Jan;23(1):134-41
pubmed: 26286195
J Clin Endocrinol Metab. 2015 Mar;100(3):841-9
pubmed: 25559399
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107
J Clin Endocrinol Metab. 2017 Apr 01;102(4):1358-1365
pubmed: 28324035
Endocr Relat Cancer. 2021 Aug 16;28(10):671-681
pubmed: 34410225
Hum Pathol. 2021 Apr;110:50-61
pubmed: 33058949
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1239-1246
pubmed: 35092681
Int J Cancer. 2020 Apr 1;146(7):1836-1840
pubmed: 31241762
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686-1695
pubmed: 29452402
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523
pubmed: 30113656
J Am Coll Surg. 2016 Apr;222(4):480-90
pubmed: 26775162
J Clin Endocrinol Metab. 2022 Mar 24;107(4):964-971
pubmed: 34850915
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer. 2017 Aug 15;123(16):3150-3158
pubmed: 28387921
Langenbecks Arch Surg. 2010 Sep;395(7):955-61
pubmed: 20694732
Endocr Pathol. 2022 Mar;33(1):155-196
pubmed: 35288842
Nat Rev Endocrinol. 2019 Sep;15(9):548-560
pubmed: 31147626